登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C18H24N4O· HCl
化学文摘社编号:
分子量:
348.87
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H/t12-,13+,14-;
SMILES string
Cl.CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c3nn(C)c4ccccc34
InChI key
QYZRTBKYBJRGJB-WQTKJZBYSA-N
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
mp
284.0-290.0 °C
solubility
H2O: >10 mg/mL
originator
Roche
storage temp.
room temp
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
盐酸格拉司琼是一种5-羟色胺5-HT3受体拮抗剂和止吐药。
Granisetron hydrochloride helps to block nausea/emesis and abdominal pain in irritable bowel syndrome, that is stimulated by chemotherapy.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
新产品
此项目有
Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron
Martin R, et al.
Neurogastroenterology and Motility, e13499-e13499 (2018)
J Vardy et al.
Breast cancer research and treatment, 136(1), 143-151 (2012-09-08)
Uncertainty remains about the optimal anti-emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer. Many patients receive dexamethasone but complain of insomnia, anxiety/agitation, and indigestion. The aim was to determine if patients receiving chemotherapy
Joseph A Roscoe et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(27), 3389-3395 (2012-08-24)
We conducted a double-blind randomized clinical trial of the following four regimens for controlling delayed nausea (DN): group 1: palonosetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3; group 2: granisetron + dexamethasone on day 1
H Saito et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(4), 1067-1073 (2012-11-03)
We evaluated the efficacy and safety of single-dose fosaprepitant in combination with intravenous granisetron and dexamethasone. Patients receiving chemotherapy including cisplatin (≥70 mg/m(2)) were eligible. A total of 347 patients (21% had received cisplatin with vomiting) were enrolled in this
Mayako Uchida et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 70(4), 343-349 (2013-02-02)
Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持